Why the study?
Does high-dose epirubicin monotherapy induce remission and improve survival in women with advanced breast cancer?
Observational (n=52)
Does high-dose epirubicin monotherapy induce remission and improve survival in women with advanced breast cancer?
High-dose epirubicin monotherapy demonstrates activity in advanced breast cancer, with 17 of 48 evaluable patients achieving remission, though significant toxicity was observed.
Answers are grounded in this paper and cite their sources.
Supports epirubicin activity in advanced breast cancer; leaves open comparative efficacy in randomized trials.
Fifty-two women with advanced breast cancer were treated with 6 cycles of epirubicin. Even though the study was started with a dose schedule of 110 mg/m2 every 3 weeks, the average treatment interval was 26 days and the median weekly dose 78% of the protocol requirement. Forty-eight patients were evaluable for response; 3 achieved a complete remission which lasted for 17, 24 and 65 weeks, respectively, and 14 a partial remission. Median survival was 32 weeks. Toxicity included nausea/vomiting (68%), anemia (24%), leukopenia (37%), thrombocytopenia (8%), alopecia (81%), stomatitis (24%), diarrhea (14%), fever (19%) and fatigue (14%). Also 1 treatment-related death occurred and 2 cases of arrhythmia. Monotherapy with high doses of epirubicin has definite activity in advanced breast cancer and deserves further study in combination with hematopoietic growth factors which might allow a higher dose intensity.
No takes yet. Share an insight, caveat, or question.
Fountzilas et al. (1991) conducted an observational in Advanced breast cancer (n=52). Epirubicin was evaluated on Response (complete and partial remission).
Synapse has enriched 10 related papers. Consider them for comparative context: